* history of or current hospitalization for covid-19. * for the current sars-cov-2 infection, any positive sars-cov-2 nucleic acid or antigen tests from any respiratory tract specimen collected \> 240 hours prior to study entry. * current need for hospitalization or immediate medical attention. * use of any prohibited medication listed in the protocol and/or use of systemic or inhaled steroids for the purpose of covid-19 treatment (new or increased dose from chronic baseline) within 30 days prior to study. * receipt of convalescent covid-19 plasma or other antibody-based anti-sars-cov-2 treatment or prophylaxis at any time prior to study entry. * receipt of other investigational treatments for sars-cov-2 any time before participating in the study (not including drugs approved and taken for other conditions/diseases or covid-19 vaccines). * known allergy/sensitivity or hypersensitivity to study drug or placebo. * any condition requiring surgery up to 7 days before participating in the study, or that is considered life threatening up to 30 days before participating in the study. * currently pregnant or breastfeeding (brii-196/brii-198, azd7442 \[iv\], azd7442 \[im\], sng001, camostat, sab-185, bms 986414+bms 986413). * in phase ii, meeting the protocol definition of being at "higher" risk of progression to hospitalization or death (azd7442 \[iv\], azd7442 \[im\], sng001, camostat, sab-185, bms 986414+bms 986413). * inflammatory skin conditions that compromise the safety of intramuscular (im) injections, or other overlying skin conditions or tattoos that would preclude the assessment of injection site reactions, per the discretion of the investigator (azd7442 \[im\]). * inflammatory skin conditions that compromise the safety of subcutaneous (sc) injections, or other overlying skin conditions or tattoos that would preclude the assessment of infection site reactions, per the discretion of the investigator (bms 986414+bms 986413). * history of coagulopathy which, in the opinion of the investigator, would preclude im injection, or use of oral or injectable anticoagulants (protocol provides more information on prohibited medications) (azd7442 \[im\]). * use of or need for chronic supplemental oxygen (sng001). * known severe liver disease prior to enrollment (defined as alt or ast \> 5 times upper limit of normal or end stage liver disease with child-pugh class c or child-pugh-turcotte score ≥ 10) (camostat). * known severe kidney disease prior to enrollment (defined as estimated glomerular filtration rate (egfr) \<30 ml/min/1.73m² or on renal-replacement therapy such as peritoneal dialysis or hemodialysis (camostat) other investigational drug protocol-defined inclusion/exclusion criteria may apply.

* history of or current hospitalization for covid-19. * for the current sars-cov-2 infection, any positive sars-cov-2 nucleic acid or antigen tests from any respiratory tract specimen collected \> 240 hours prior to study entry. * current need for hospitalization or immediate medical attention. * use of any prohibited medication listed in the protocol and/or use of systemic or inhaled steroids for the purpose of covid-19 treatment (new or increased dose from chronic baseline) within 30 days prior to study. * receipt of convalescent covid-19 plasma or other antibody-based anti-sars-cov-2 treatment or prophylaxis at any time prior to study entry. * receipt of other investigational treatments for sars-cov-2 any time before participating in the study (not including drugs approved and taken for other conditions/diseases or covid-19 vaccines). * known allergy/sensitivity or hypersensitivity to study drug or placebo. * any condition requiring surgery up to 7 days before participating in the study, or that is considered life threatening up to 30 days before participating in the study. * currently pregnant or breastfeeding (brii-196/brii-198, azd7442 \[iv\], azd7442 \[im\], sng001, camostat, sab-185, bms 986414+bms 986413). * in phase ii, meeting the protocol definition of being at "higher" risk of progression to hospitalization or death (azd7442 \[iv\], azd7442 \[im\], sng001, camostat, sab-185, bms 986414+bms 986413). * inflammatory skin conditions that compromise the safety of intramuscular (im) injections, or other overlying skin conditions or tattoos that would preclude the assessment of injection site reactions, per the discretion of the investigator (azd7442 \[im\]). * inflammatory skin conditions that compromise the safety of subcutaneous (sc) injections, or other overlying skin conditions or tattoos that would preclude the assessment of infection site reactions, per the discretion of the investigator (bms 986414+bms 986413). * history of coagulopathy which, in the opinion of the investigator, would preclude im injection, or use of oral or injectable anticoagulants (protocol provides more information on prohibited medications) (azd7442 \[im\]). * use of or need for chronic supplemental oxygen (sng001). * known severe liver disease prior to enrollment (defined as alt or ast \> 5 times upper limit of normal or end stage liver disease with child-pugh class c or child-pugh-turcotte score ≥ 10) (camostat). * known severe kidney disease prior to enrollment (defined as estimated glomerular filtration rate (egfr) \<30 ml/min/1.73m² or on renal-replacement therapy such as peritoneal dialysis or hemodialysis (camostat) other investigational drug protocol-defined inclusion/exclusion criteria may apply.

- history of or current hospitalization for covid-19. - for the current sars-cov-2 infection, any positive sars-cov-2 nucleic acid or antigen tests from any respiratory tract specimen collected > 240 hours prior to study entry. - current need for hospitalization or immediate medical attention. - use of any prohibited medication listed in the protocol and/or use of systemic or inhaled steroids for the purpose of covid-19 treatment (new or increased dose from chronic baseline) within 30 days prior to study. - receipt of convalescent covid-19 plasma or other antibody-based anti-sars-cov-2 treatment or prophylaxis at any time prior to study entry. - receipt of other investigational treatments for sars-cov-2 any time before participating in the study (not including drugs approved and taken for other conditions/diseases or covid-19 vaccines). - known allergy/sensitivity or hypersensitivity to study drug or placebo. - any condition requiring surgery up to 7 days before participating in the study, or that is considered life threatening up to 30 days before participating in the study. - currently pregnant or breastfeeding (brii-196/brii-198, azd7442 [iv], azd7442 [im], sng001, camostat, sab-185, bms 986414+bms 986413). - in phase ii, meeting the protocol definition of being at "higher" risk of progression to hospitalization or death (azd7442 [iv], azd7442 [im], sng001, camostat, sab-185, bms 986414+bms 986413). - inflammatory skin conditions that compromise the safety of intramuscular (im) injections, or other overlying skin conditions or tattoos that would preclude the assessment of injection site reactions, per the discretion of the investigator (azd7442 [im]). - inflammatory skin conditions that compromise the safety of subcutaneous (sc) injections, or other overlying skin conditions or tattoos that would preclude the assessment of infection site reactions, per the discretion of the investigator (bms 986414+bms 986413). - history of coagulopathy which, in the opinion of the investigator, would preclude im injection, or use of oral or injectable anticoagulants (protocol provides more information on prohibited medications) (azd7442 [im]). - use of or need for chronic supplemental oxygen (sng001). - known severe liver disease prior to enrollment (defined as alt or ast > 5 times upper limit of normal or end stage liver disease with child-pugh class c or child-pugh-turcotte score ≥ 10) (camostat). - known severe kidney disease prior to enrollment (defined as estimated glomerular filtration rate (egfr) <30 ml/min/1.73m² or on renal-replacement therapy such as peritoneal dialysis or hemodialysis (camostat) other investigational drug protocol-defined inclusion/exclusion criteria may apply.

- history of or current hospitalization for covid-19. - for the current sars-cov-2 infection, any positive sars-cov-2 nucleic acid or antigen tests from any respiratory tract specimen collected > 240 hours prior to study entry. - current need for hospitalization or immediate medical attention. - use of any prohibited medication listed in the protocol and/or use of systemic or inhaled steroids for the purpose of covid-19 treatment (new or increased dose from chronic baseline) within 30 days prior to study. - receipt of convalescent covid-19 plasma or other antibody-based anti-sars-cov-2 treatment or prophylaxis at any time prior to study entry. - receipt of other investigational treatments for sars-cov-2 any time before participating in the study (not including drugs approved and taken for other conditions/diseases or covid-19 vaccines). - known allergy/sensitivity or hypersensitivity to study drug or placebo. - any condition requiring surgery up to 7 days before participating in the study, or that is considered life threatening up to 30 days before participating in the study. - currently pregnant or breastfeeding (brii-196/brii-198, azd7442 [iv], azd7442 [im], sng001, camostat, sab-185, bms 986414+bms 986413). - in phase ii, meeting the protocol definition of being at "higher" risk of progression to hospitalization or death (azd7442 [iv], azd7442 [im], sng001, camostat, sab-185, bms 986414+bms 986413). - inflammatory skin conditions that compromise the safety of intramuscular (im) injections, or other overlying skin conditions or tattoos that would preclude the assessment of injection site reactions, per the discretion of the investigator (azd7442 [im]). - inflammatory skin conditions that compromise the safety of subcutaneous (sc) injections, or other overlying skin conditions or tattoos that would preclude the assessment of infection site reactions, per the discretion of the investigator (bms 986414+bms 986413). - history of coagulopathy which, in the opinion of the investigator, would preclude im injection, or use of oral or injectable anticoagulants (protocol provides more information on prohibited medications) (azd7442 [im]). - use of or need for chronic supplemental oxygen (sng001). - known severe liver disease prior to enrollment (defined as alt or ast > 5 times upper limit of normal or end stage liver disease with child-pugh class c or child-pugh-turcotte score ≥ 10) (camostat). - known severe kidney disease prior to enrollment (defined as estimated glomerular filtration rate (egfr) <30 ml/min/1.73m² or on renal-replacement therapy such as peritoneal dialysis or hemodialysis (camostat) other investigational drug protocol-defined inclusion/exclusion criteria may apply.

- history of or current hospitalization for covid-19. - for the current sars-cov-2 infection, any positive sars-cov-2 molecular test from any respiratory tract specimen collected more than 10 days prior to study entry. - current need for hospitalization or immediate medical attention. - any use of the following medications up to 30 days before participating in the study: - hydroxychloroquine (except for long-term autoimmune diseases) - chloroquine and/or ivermectin (unless used for parasitic infection) - remdesivir, systemic and inhaled steroids (unless used for long-term conditions) - hiv protease inhibitors (unless used long-term for hiv infection) - receipt of convalescent covid-19 plasma or other antibody-based anti-sars-cov-2 treatment or prophylaxis at any time prior to study entry. - receipt of other investigational treatments for sars-cov-2 any time before participating in the study (not including drugs approved and taken for other conditions/diseases). - known allergy/sensitivity or hypersensitivity to study drug or placebo. - any condition requiring surgery up to 7 days before participating in the study, or that is considered life threatening up to 30 days before participating in the study. - currently pregnant or breastfeeding (brii-196/brii-198, azd7442 [iv], azd7442 [im], sng001, camostat, sab-185, c135-ls+c144-ls). - in phase ii, meeting the protocol definition of being at "higher risk of progression to severe covid-19" (azd7442 [iv], azd7442 [im], sng001, camostat, sab-185, c135-ls+c144-ls). - inflammatory skin conditions that compromise the safety of intramuscular (im) injections, or other overlying skin conditions or tattoos that would preclude the assessment of injection site reactions, per the discretion of the investigator (azd7442 [im]). - inflammatory skin conditions that compromise the safety of subcutaneous (sc) injections, or other overlying skin conditions or tattoos that would preclude the assessment of infection site reactions, per the discretion of the investigator (c135-ls+c144-ls). - history of coagulopathy which, in the opinion of the investigator, would preclude im injection, or use of oral or injectable anticoagulants (protocol provides more information on prohibited medications) (azd7442 [im]). - use of or need for chronic supplemental oxygen (sng001). - known severe liver disease prior to enrollment (defined as alt or ast > 5 times upper limit of normal or end stage liver disease with child-pugh class c or child-pugh-turcotte score ≥ 10) (camostat). - known severe kidney disease prior to enrollment (defined as estimated glomerular filtration rate (egfr) <30 ml/min/1.73m² or on renal-replacement therapy such as peritoneal dialysis or hemodialysis (camostat) other investigational drug protocol-defined inclusion/exclusion criteria may apply.

- history of or current hospitalization for covid-19. - for the current sars-cov-2 infection, any positive sars-cov-2 molecular test from any respiratory tract specimen collected more than 10 days prior to study entry. - current need for hospitalization or immediate medical attention. - any use of the following medications up to 30 days before participating in the study: - hydroxychloroquine (except for long-term autoimmune diseases) - chloroquine and/or ivermectin (unless used for parasitic infection) - remdesivir, systemic and inhaled steroids (unless used for long-term conditions) - hiv protease inhibitors (unless used long-term for hiv infection) - receipt of convalescent covid-19 plasma or other antibody-based anti-sars-cov-2 treatment or prophylaxis at any time prior to study entry. - receipt of other investigational treatments for sars-cov-2 any time before participating in the study (not including drugs approved and taken for other conditions/diseases). - known allergy/sensitivity or hypersensitivity to study drug or placebo. - any condition requiring surgery up to 7 days before participating in the study, or that is considered life threatening up to 30 days before participating in the study. - currently pregnant or breastfeeding (brii-196/brii-198, azd7442 [iv], azd7442 [im], sng001, camostat, sab-185, c135-ls+c144-ls). - in phase ii, meeting the protocol definition of being at "higher risk of progression to severe covid-19" (azd7442 [iv], azd7442 [im], sng001, camostat, sab-185, c135-ls+c144-ls). - inflammatory skin conditions that compromise the safety of intramuscular (im) injections, or other overlying skin conditions or tattoos that would preclude the assessment of injection site reactions, per the discretion of the investigator (azd7442 [im]). - inflammatory skin conditions that compromise the safety of subcutaneous (sc) injections, or other overlying skin conditions or tattoos that would preclude the assessment of infection site reactions, per the discretion of the investigator (c135-ls+c144-ls). - history of coagulopathy which, in the opinion of the investigator, would preclude im injection, or use of oral or injectable anticoagulants (protocol provides more information on prohibited medications) (azd7442 [im]). - use of or need for chronic supplemental oxygen (sng001). - known severe liver disease prior to enrollment (defined as alt or ast > 5 times upper limit of normal or end stage liver disease with child-pugh class c or child-pugh-turcotte score ≥ 10) (camostat). - known severe kidney disease prior to enrollment (defined as estimated glomerular filtration rate (egfr) <30 ml/min/1.73m² or on renal-replacement therapy such as peritoneal dialysis or hemodialysis (camostat) other investigational drug protocol-defined inclusion/exclusion criteria may apply.

- history of or current hospitalization for covid-19. - for the current sars-cov-2 infection, any positive sars-cov-2 molecular test from any respiratory tract specimen collected more than 10 days prior to study entry. - current need for hospitalization or immediate medical attention. - any use of the following medications up to 30 days before participating in the study: - hydroxychloroquine (except for long-term autoimmune diseases) - chloroquine and/or ivermectin (unless used for parasitic infection) - remdesivir, systemic and inhaled steroids (unless used for long-term conditions) - hiv protease inhibitors (unless used long-term for hiv infection) - receipt of convalescent covid-19 plasma or other antibody-based anti-sars-cov-2 treatment or prophylaxis at any time prior to study entry. - receipt of other investigational treatments for sars-cov-2 any time before participating in the study (not including drugs approved and taken for other conditions/diseases). - known allergy/sensitivity or hypersensitivity to study drug or placebo. - any condition requiring surgery up to 7 days before participating in the study, or that is considered life threatening up to 30 days before participating in the study. - currently pregnant or breastfeeding (brii-196/brii-198, azd7442 [iv], azd7442 [im], sng001, camostat, sab-185, c135-ls+c144-ls). - inflammatory skin conditions that compromise the safety of intramuscular (im) injections, or other overlying skin conditions or tattoos that would preclude the assessment of injection site reactions, per the discretion of the investigator (azd7442 [im]). - inflammatory skin conditions that compromise the safety of subcutaneous (sc) injections, or other overlying skin conditions or tattoos that would preclude the assessment of infection site reactions, per the discretion of the investigator (c135-ls+c144-ls). - history of coagulopathy which, in the opinion of the investigator, would preclude im injection, or use of oral or injectable anticoagulants (protocol provides more information on prohibited medications) (azd7442 [im]). - use of or need for chronic supplemental oxygen (sng001). - known severe liver disease prior to enrollment (defined as alt or ast > 5 times upper limit of normal or end stage liver disease with child-pugh class c or child-pugh-turcotte score ≥ 10) (camostat). - known severe kidney disease prior to enrollment (defined as estimated glomerular filtration rate (egfr) <30 ml/min/1.73m² or on renal-replacement therapy such as peritoneal dialysis or hemodialysis (camostat). - meet the protocol definition of being at "higher" risk of progression to sever covid-19 (c135-ls+c144-ls). other investigational drug protocol-defined inclusion/exclusion criteria may apply.

- history of or current hospitalization for covid-19. - for the current sars-cov-2 infection, any positive sars-cov-2 molecular test from any respiratory tract specimen collected more than 10 days prior to study entry. - current need for hospitalization or immediate medical attention. - any use of the following medications up to 30 days before participating in the study: - hydroxychloroquine (except for long-term autoimmune diseases) - chloroquine and/or ivermectin (unless used for parasitic infection) - remdesivir, systemic and inhaled steroids (unless used for long-term conditions) - hiv protease inhibitors (unless used long-term for hiv infection) - receipt of convalescent covid-19 plasma or other antibody-based anti-sars-cov-2 treatment or prophylaxis at any time prior to study entry. - receipt of other investigational treatments for sars-cov-2 any time before participating in the study (not including drugs approved and taken for other conditions/diseases). - known allergy/sensitivity or hypersensitivity to study drug or placebo. - any condition requiring surgery up to 7 days before participating in the study, or that is considered life threatening up to 30 days before participating in the study. - currently pregnant or breastfeeding (brii-196/brii-198, azd7442 [iv], azd7442 [im], sng001, camostat, sab-185, c135-ls+c144-ls). - inflammatory skin conditions that compromise the safety of intramuscular (im) injections, or other overlying skin conditions or tattoos that would preclude the assessment of injection site reactions, per the discretion of the investigator (azd7442 [im]). - inflammatory skin conditions that compromise the safety of subcutaneous (sc) injections, or other overlying skin conditions or tattoos that would preclude the assessment of infection site reactions, per the discretion of the investigator (c135-ls+c144-ls). - history of coagulopathy which, in the opinion of the investigator, would preclude im injection, or use of oral or injectable anticoagulants (protocol provides more information on prohibited medications) (azd7442 [im]). - use of or need for chronic supplemental oxygen (sng001). - known severe liver disease prior to enrollment (defined as alt or ast > 5 times upper limit of normal or end stage liver disease with child-pugh class c or child-pugh-turcotte score ≥ 10) (camostat). - known severe kidney disease prior to enrollment (defined as estimated glomerular filtration rate (egfr) <30 ml/min/1.73m² or on renal-replacement therapy such as peritoneal dialysis or hemodialysis (camostat). - meet the protocol definition of being at "higher" risk of progression to sever covid-19 (c135-ls+c144-ls). other investigational drug protocol-defined inclusion/exclusion criteria may apply.

- history of or current hospitalization for covid-19. - for the current sars-cov-2 infection, any positive sars-cov-2 molecular test from any respiratory tract specimen collected more than 10 days prior to study entry. - current need for hospitalization or immediate medical attention. - any use of the following medications up to 30 days before participating in the study: - hydroxychloroquine (except for long-term autoimmune diseases) - chloroquine and/or ivermectin (unless used for parasitic infection) - remdesivir, systemic and inhaled steroids (unless used for long-term conditions) - hiv protease inhibitors (unless used long-term for hiv infection) - receipt of convalescent covid-19 plasma or other antibody-based anti-sars-cov-2 treatment or prophylaxis at any time prior to study entry. - receipt of a sars-cov-2 vaccine within 6 weeks prior to participating in the study. - receipt of other investigational treatments for sars-cov-2 any time before participating in the study (not including drugs approved and taken for other conditions/diseases). - known allergy/sensitivity or hypersensitivity to study drug or placebo. - any condition requiring surgery up to 7 days before participating in the study, or that is considered life threatening up to 30 days before participating in the study. - currently pregnant or breastfeeding (brii-196/brii-198, azd7442 [iv], azd7442 [im], sng001, camostat, c135-ls+c144-ls). - inflammatory skin conditions that compromise the safety of intramuscular (im) injections, or other overlying skin conditions or tattoos that would preclude the assessment of injection site reactions, per the discretion of the investigator (azd7442 [im]). - inflammatory skin conditions that compromise the safety of subcutaneous (sc) injections, or other overlying skin conditions or tattoos that would preclude the assessment of infection site reactions, per the discretion of the investigator (c135-ls+c144-ls). - history of coagulopathy which, in the opinion of the investigator, would preclude im injection, or use of oral or injectable anticoagulants (protocol provides more information on prohibited medications) (azd7442 [im]). - use of or need for chronic supplemental oxygen (sng001). - known severe liver disease prior to enrollment (defined as alt or ast > 5 times upper limit of normal or end stage liver disease with child-pugh class c or child-pugh-turcotte score ≥ 10) (camostat). - known severe kidney disease prior to enrollment (defined as estimated glomerular filtration rate (egfr) <30 ml/min/1.73m² or on renal-replacement therapy such as peritoneal dialysis or hemodialysis (camostat). - meet the protocol definition of being at "higher" risk of progression to sever covid-19 (c135-ls+c144-ls). other investigational drug protocol-defined inclusion/exclusion criteria may apply.

- history of or current hospitalization for covid-19. - for the current sars-cov-2 infection, any positive sars-cov-2 molecular test from any respiratory tract specimen collected more than 10 days prior to study entry. - current need for hospitalization or immediate medical attention. - any use of the following medications up to 30 days before participating in the study: - hydroxychloroquine (except for long-term autoimmune diseases) - chloroquine and/or ivermectin (unless used for parasitic infection) - remdesivir, systemic and inhaled steroids (unless used for long-term conditions) - hiv protease inhibitors (unless used long-term for hiv infection) - receipt of convalescent covid-19 plasma or other antibody-based anti-sars-cov-2 treatment or prophylaxis at any time prior to study entry. - receipt of a sars-cov-2 vaccine within 6 weeks prior to participating in the study. - receipt of other investigational treatments for sars-cov-2 any time before participating in the study (not including drugs approved and taken for other conditions/diseases). - known allergy/sensitivity or hypersensitivity to study drug or placebo. - any condition requiring surgery up to 7 days before participating in the study, or that is considered life threatening up to 30 days before participating in the study. - currently pregnant or breastfeeding (brii-196/brii-198, azd7442 [iv], azd7442 [im], sng001, camostat, c135-ls+c144-ls). - inflammatory skin conditions that compromise the safety of intramuscular (im) injections, or other overlying skin conditions or tattoos that would preclude the assessment of injection site reactions, per the discretion of the investigator (azd7442 [im]). - inflammatory skin conditions that compromise the safety of subcutaneous (sc) injections, or other overlying skin conditions or tattoos that would preclude the assessment of infection site reactions, per the discretion of the investigator (c135-ls+c144-ls). - history of coagulopathy which, in the opinion of the investigator, would preclude im injection, or use of oral or injectable anticoagulants (protocol provides more information on prohibited medications) (azd7442 [im]). - use of or need for chronic supplemental oxygen (sng001). - known severe liver disease prior to enrollment (defined as alt or ast > 5 times upper limit of normal or end stage liver disease with child-pugh class c or child-pugh-turcotte score ≥ 10) (camostat). - known severe kidney disease prior to enrollment (defined as estimated glomerular filtration rate (egfr) <30 ml/min/1.73m² or on renal-replacement therapy such as peritoneal dialysis or hemodialysis (camostat). - meet the protocol definition of being at "higher" risk of progression to sever covid-19 (c135-ls+c144-ls). other investigational drug protocol-defined inclusion/exclusion criteria may apply.

- history of or current hospitalization for covid-19. - for the current sars-cov-2 infection, any positive sars-cov-2 molecular test from any respiratory tract specimen collected more than 10 days prior to study entry. - current need for hospitalization or immediate medical attention. - any use of the following medications up to 30 days before participating in the study: - hydroxychloroquine (except for long-term autoimmune diseases) - chloroquine and/or ivermectin (unless used for parasitic infection) - remdesivir, systemic and inhaled steroids (unless used for long-term conditions) - hiv protease inhibitors (unless used long-term for hiv infection) - receipt of convalescent covid-19 plasma or other antibody-based anti-sars-cov-2 treatment or prophylaxis at any time prior to study entry. - receipt of a sars-cov-2 vaccine within 6 weeks prior to participating in the study. - receipt of other investigational treatments for sars-cov-2 any time before participating in the study (not including drugs approved and taken for other conditions/diseases). - known allergy/sensitivity or hypersensitivity to study drug or placebo. - any condition requiring surgery up to 7 days before participating in the study, or that is considered life threatening up to 30 days before participating in the study. - currently pregnant or breastfeeding (brii-196/brii-198, azd7442 [iv], azd7442 [im], sng001, camostat). - inflammatory skin conditions that compromise the safety of intramuscular (im) injections, or other overlying skin conditions or tattoos that would preclude the assessment of injection site reactions, per the discretion of the investigator (azd7442 [im]). - history of coagulopathy which, in the opinion of the investigator, would preclude im injection, or use of oral or injectable anticoagulants (protocol provides more information on prohibited medications) (azd7442 [im]). - use of or need for chronic supplemental oxygen (sng001). - known severe liver disease prior to enrollment (defined as alt or ast > 5 times upper limit of normal or end stage liver disease with child-pugh class c or child-pugh-turcotte score ≥ 10) (camostat). - known severe kidney disease prior to enrollment (defined as estimated glomerular filtration rate (egfr) <30 ml/min/1.73m² or on renal-replacement therapy such as peritoneal dialysis or hemodialysis (camostat). other investigational drug protocol-defined inclusion/exclusion criteria may apply.

- history of or current hospitalization for covid-19. - for the current sars-cov-2 infection, any positive sars-cov-2 molecular test from any respiratory tract specimen collected more than 10 days prior to study entry. - current need for hospitalization or immediate medical attention. - any use of the following medications up to 30 days before participating in the study: - hydroxychloroquine (except for long-term autoimmune diseases) - chloroquine and/or ivermectin (unless used for parasitic infection) - remdesivir, systemic and inhaled steroids (unless used for long-term conditions) - hiv protease inhibitors (unless used long-term for hiv infection) - receipt of convalescent covid-19 plasma or other antibody-based anti-sars-cov-2 treatment or prophylaxis at any time prior to study entry. - receipt of a sars-cov-2 vaccine within 6 weeks prior to participating in the study. - receipt of other investigational treatments for sars-cov-2 any time before participating in the study (not including drugs approved and taken for other conditions/diseases). - known allergy/sensitivity or hypersensitivity to study drug or placebo. - any condition requiring surgery up to 7 days before participating in the study, or that is considered life threatening up to 30 days before participating in the study. - currently pregnant or breastfeeding (brii-196/brii-198, azd7442 [iv], azd7442 [im], sng001, camostat). - inflammatory skin conditions that compromise the safety of intramuscular (im) injections, or other overlying skin conditions or tattoos that would preclude the assessment of injection site reactions, per the discretion of the investigator (azd7442 [im]). - history of coagulopathy which, in the opinion of the investigator, would preclude im injection, or use of oral or injectable anticoagulants (protocol provides more information on prohibited medications) (azd7442 [im]). - use of or need for chronic supplemental oxygen (sng001). - known severe liver disease prior to enrollment (defined as alt or ast > 5 times upper limit of normal or end stage liver disease with child-pugh class c or child-pugh-turcotte score ≥ 10) (camostat). - known severe kidney disease prior to enrollment (defined as estimated glomerular filtration rate (egfr) <30 ml/min/1.73m² or on renal-replacement therapy such as peritoneal dialysis or hemodialysis (camostat). other investigational drug protocol-defined inclusion/exclusion criteria may apply.

- history of or current hospitalization for covid-19. - current need for hospitalization or immediate medical attention. - any use of the following medications up to 30 days before participating in the study: - hydroxychloroquine (except for long-term autoimmune diseases) - chloroquine and/or ivermectin (unless used for parasitic infection) - remdesivir, systemic and inhaled steroids (unless used for long-term conditions) - hiv protease inhibitors (unless used long-term for hiv infection) - receipt of plasma from a person who recovered from covid-19 any time before participating in the study. - receipt of a sars-cov-2 vaccine any time before participating in the study. - receipt of other investigational treatments for sars-cov-2 any time before participating in the study (not including drugs approved and taken for other conditions/diseases). - receipt of systemic steroids (e.g. prednisone, dexamethasone) or inhaled steroids up to 30 days before participating in the study, unless this is a stable dose for a long-term condition. - known allergy/sensitivity or hypersensitivity to study drug or placebo. - any condition requiring surgery up to 7 days before participating in the study, or that is considered life threatening up to 30 days before participating in the study. other investigational drug protocol-defined inclusion/exclusion criteria may apply.

- history of or current hospitalization for covid-19. - current need for hospitalization or immediate medical attention. - any use of the following medications up to 30 days before participating in the study: - hydroxychloroquine (except for long-term autoimmune diseases) - chloroquine and/or ivermectin (unless used for parasitic infection) - remdesivir, systemic and inhaled steroids (unless used for long-term conditions) - hiv protease inhibitors (unless used long-term for hiv infection) - receipt of plasma from a person who recovered from covid-19 any time before participating in the study. - receipt of a sars-cov-2 vaccine any time before participating in the study. - receipt of other investigational treatments for sars-cov-2 any time before participating in the study (not including drugs approved and taken for other conditions/diseases). - receipt of systemic steroids (e.g. prednisone, dexamethasone) or inhaled steroids up to 30 days before participating in the study, unless this is a stable dose for a long-term condition. - known allergy/sensitivity or hypersensitivity to study drug or placebo. - any condition requiring surgery up to 7 days before participating in the study, or that is considered life threatening up to 30 days before participating in the study. other investigational drug protocol-defined inclusion/exclusion criteria may apply.